SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and product pipeline.
“We are excited about the progress we are making on our CD101 IV and Cloudbreak™ programs, which we discussed at our recent investor day,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We anticipate announcing topline data from our STRIVE Phase 2 trial of CD101 IV in the fourth quarter, and are advancing CD201 through IND-enabling studies. Our financial position remains strong, and I look forward to providing an update on our continued progress as the year unfolds.”
“We are excited about the progress we are making on our CD101 IV and Cloudbreak™ programs, which we discussed at our recent investor day,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We anticipate announcing topline data from our STRIVE Phase 2 trial of CD101 IV in the fourth quarter, and are advancing CD201 through IND-enabling studies. Our financial position remains strong, and I look forward to providing an update on our continued progress as the year unfolds.”
